Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06945120

ACT Lung Health Intervention: Phase Two

Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Dana-Farber Cancer Institute · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Detailed description

This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer. Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance. The research study procedures include screening for eligibility, questionnaires, and saliva tests. It is expected participation in this study will last about 6 months. About 50 participants are expected to take part in this research study. The National Cancer Institute is providing funding for this trial.

Conditions

Interventions

TypeNameDescription
BEHAVIORALACT Lung Health InterventionAn Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.

Timeline

Start date
2025-11-04
Primary completion
2026-11-30
Completion
2026-12-31
First posted
2025-04-25
Last updated
2026-03-13

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT06945120. Inclusion in this directory is not an endorsement.